SCHEDULE: Acorn Funds Boost Stake in Y-mAbs to 7.0%
Beneficial Ownership Report
Acorn Bioventures and related entities, including Anders Hove, have increased their beneficial ownership in Y-mAbs Therapeutics, Inc. to 7.0% of outstanding common stock.
Summary
- Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove collectively beneficially own 3,096,297 shares of Y-mAbs Therapeutics, Inc. common stock.
- This aggregate ownership represents 7.0% of the issuer's common stock outstanding.
- The percentage is calculated based on 45,438,420 shares of common stock outstanding as of August 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
- Anders Hove, as Manager of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, is deemed to beneficially own the shares held by these entities.
- The securities were not acquired and are not held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It indicates a significant institutional investment.
Future Outlook
NA
Industry Context
This filing indicates a significant stake held by a specialized bioventures fund in a biotechnology company. Such investments are common in the biotech sector, where specialized funds often take positions in companies developing novel therapies.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Acorn Bioventures may be viewed positively by other shareholders as it signals confidence from a specialized investor. It also provides transparency regarding major ownership positions.
Key Dates
| Date | Description |
|---|---|
| 08/04/2025 | Date as of which 45,438,420 shares of Common Stock were reported outstanding in the Issuer's Form 10-Q. |
| 08/08/2025 | Date Issuer's Quarterly Report on Form 10-Q for the period ended June 30, 2025, was filed with the SEC. |
| 08/14/2025 | Date of event which required the filing of this statement. |
| 08/15/2025 | Date of filing and signature. |
Keywords
Y-mAbs Therapeutics, Acorn Bioventures, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.